Clinical Trials Browser

NIH × Interventional × Neurofibroma, Plexiform × Clear all

NCT06507748 2026-06-05

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Phase NA Recruiting

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 1 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT02390752 2026-06-01

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Phase 1 Recruiting

CNSLymphoidOther hematologic neoplasmSarcoma

Sarcoma, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03531814 2024-06-11

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

Phase NA Completed

12 enrolled 18 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02471339 2022-06-14

Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain

Phase 3 Completed

66 enrolled 17 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00727233 2019-12-12

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Phase 1 Completed

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2 Withdrawn

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT00076102 2018-04-23

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Phase 2 Completed

36 enrolled 13 charts

Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibroma, Plexiform

NCT00021541 2018-04-17

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Phase 2 Completed

62 enrolled 13 charts

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Phase 2 Terminated

26 enrolled 8 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00053937 2015-04-30

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

Phase 1 Completed

CNSOther neoplasm

Neurofibromatosis 1, Precancerous Conditions, Neurofibroma, Plexiform